Anavex Life Sciences Corp. · NASDAQ:AVXL
Anavex Life Sciences — Proxy Contest (September 2026)
25 slides from Anavex Life Sciences's proxy contest presentation, September 2026
Slide 1: The Right Board to Drive Long-Term Value for Stockholders
The Right Board to Drive Long-Term Value for Stockholders September 2026
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company’s plans, strategies and expectations regarding
Slide 3: Executive Summary
XY anevex NCES Cor Executive Summary
Slide 4: Anavex's Highly Qualified Nominees are the Right Choice to Oversee the Company's Clear Strategy
Anavex’s Highly Qualified Nominees are the Right Choice to Oversee the Company’s Clear Strategy to Drive Long-Term Value • The Special Committee of the Board appointed Dr. Terrie Kellmeyer, a career drug-development executive and former SVP of Clinical Development at Anavex, as interim CEO, and the
Slide 5: Anavex is Executing on a Clear Strategy to Drive Long-Term Stockholder Value
Anavex is Executing on a Clear Strategy to Drive Long-Term Stockholder Value 5
Slide 6: Anavex is Dedicated to Advancing Brain Health by Developing Innovative Oral Medicines
Anavex is Dedicated to Advancing Brain Health by Developing Innovative Oral Medicines Designed to Improve Patients Lives Anavex is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, including early Alzheimer's disease, Rett syndrome, and Fragile X s
Slide 7: Pipeline Progress Across Three CNS Programs with High Potential
Pipeline Progress1 Across Three CNS Programs with High Potential FDA Discovery Preclinical Phase 1 Phase 2 Phase 3 Review US Regulatory Goals Alzheimer’s Disease Align on US clinical Early Alzheimer’s disease development strategy Rare Neurodevelopmental Disorders Align on US Phase 3 protocol Rett sy
Slide 8: Strong Leadership with Clear Strategy for Long-Term Value Creation
Strong Leadership with Clear Strategy for Long-Term Value Creation Recently refreshed and streamlined its Scientific Advisory Board to a focused group of Alzheimer’s disease key opinion leaders and treating physicians Terrie Kellmeyer, Sandra Boenisch, Daniel Klamer, Ph.D. CPA, CGA PhD, MS, MBA Inte
Slide 9: Anavex's Highly Qualified Nominees are the Right Choice to Oversee Strategy
Anavex’s Highly Qualified Nominees are the Right Choice to Oversee Strategy and Drive Long-Term Value for Stockholders 9
Slide 10: Incumbent Directors Acted Decisively to Establish a Governance Structure
The Incumbent Directors Standing for Election Acted Decisively to Establish a Governance Structure that Preserved Board Oversight and Continuity while Addressing Former CEO Christopher Missling’s Refusal to Resign from the Board 2026 April 30 May 4 May 11 May 20 July 30 The Special Committee, The Sp
Slide 11: Incumbent Directors Acted Decisively to Establish a Governance Structure
The Incumbent Directors Standing for Election Acted Decisively to Establish a Governance Structure that Preserved Board Oversight and Continuity while Addressing Former CEO Christopher Missling’s Refusal to Resign from the Board 2026 July 31 July 31 August 25 August 28 Anavex files its preliminary p
Slide 12: Anavex's Nominees are Highly Qualified and Independent
Anavex’s Nominees are Highly Qualified and Independent Incumbent New Nominee Jiong Ma (chair), Peter Donhauser, Axel Paeger, Ph.D. D.O. M.D., MBA, MBI Experienced operator 20+ years of experience CEO of a leading with 30+ years of in integrated medical European healthcare experience investing in car
Slide 13: Refreshed Board to Have Complementary Skillsets and Experience
Refreshed Board to Have Complementary Skillsets and Experience Incumbent New Nominee Jiong Peter Axel Paeger, Gautam Adrian Claus van Skills and Experience Ma, Donhauser, M.D., MBA, Patel, Senderowicz, der Velden, Total Ph.D. D.O. MBI MBA M.D. Ph.D. Independent Director ✓ ✓ ✓ ✓ ✓ ✓ 6 of 6 CEO / Oper
Slide 14: Anavex's New Independent Nominees Bring Deep, Relevant Pharma Experience
Anavex’s New Independent Nominees Bring Deep, Relevant Pharma Experience at the Board and Executive Level Gautam Patel, MBA • Managing Director and a member of the Investment Committee at Tarsadia Investments Upon election of Mr. Patel and Dr. Senderowicz, • He has served on the Board of Amneal Phar
Slide 15: PVG Asset Management has Offered No Compelling Plan and is Trying to Gain Control
PVG Asset Management has Offered No Compelling Plan and is Trying to Gain Control of Anavex Without Paying Stockholders a Premium 15
Slide 16: Electing PVG's Nominees Would be HIGHLY Risky and Potentially Value-Destructive
Electing PVG’s Nominees Would be HIGHLY Risky and Potentially Value-Destructive Patrick S. Adams Dale Curtis Hogue, Jr. Rene Mora No drug development, During his <2-year No public company clinical or regulatory tenure as CEO of board experience experience Alaunos Therapeutics, No drug develo
Slide 17: PVG's Nominees are Not Additive and Lack Relevant Experience
PVG’s Nominees are Not Additive and Lack Relevant Experience Gautam Patel, Claus van der M.D., MBA, MBI Senderowicz, Velden, Ph.D. Axel Paeger, Donhauser, Dale Curtis John Boris Rene Mora Hogue, Jr. Jiong Ma, Patrick S. Ziegesar Ralf von Kolbert Adams Adrian Jason Peter Ph.D. MBA M.D. D.O. Skills an
Slide 18: PVG has Presented No Credible Strategy: Board of Directors
PVG has Presented No Credible Strategy or Ideas to Create Long-term Value Topic: Board of Directors PVG’s “Plan” Anavex Response Reconstruct the Board with • Anavex's slate combines directors with direct biotech operating and drug experienced executives and development experience with new nominees w
Slide 19: PVG has Presented No Credible Strategy: Pipeline (1/2)
PVG has Presented No Credible Strategy or Ideas to Create Long-term Value Topic: Pipeline (1/2) PVG’s “Plan” Anavex Response We would explore starting the • Anavex is already advancing key blarcamesine programs, with tangible milestones already achieved Phase 3 Alzheimer’s trial for across all three
Slide 20: PVG has Presented No Credible Strategy: Pipeline (2/2)
PVG has Presented No Credible Strategy or Ideas to Create Long-term Value Topic: Pipeline (2/2) PVG’s “Plan” Anavex Response We would explore partnering with • Anavex has already secured non-dilutive funding support from third-party organizations, including research big drug companies and pursue gra
Slide 21: PVG has Presented No Credible Strategy: Management Team
PVG has Presented No Credible Strategy or Ideas to Create Long-term Value Topic: Management Team PVG’s “Plan” Anavex Response Explore hiring an experienced CEO with • Anavex has already appointed Dr. Terrie Kellmeyer as Interim CEO, a leader with over 30 years of a track record, who has led other te
Slide 22: PVG has Presented No Credible Strategy: IR and Public Listing
PVG has Presented No Credible Strategy or Ideas to Create Long-term Value Topic: IR and Public Listing PVG’s “Plan” Anavex Response It is critical to keep the Company’s • We are current on our financials and continue to work diligently with Nasdaq to officially fully common stock listed on the Nasda
Slide 23: Conclusion
Conclusion wWoanevex 2
Slide 24: Anavex's Highly Qualified Nominees are the Right Choice to Oversee the Company's Clear Strategy
Anavex’s Highly Qualified Nominees are the Right Choice to Oversee the Company’s Clear Strategy to Drive Long-Term Value • The Special Committee of the Board appointed Dr. Terrie Kellmeyer, a career drug-development executive and former SVP of Clinical Development at Anavex, as interim CEO, and the
Slide 25: Reject PVG's Attempt to Take Control of Anavex
Reject PVG’s Attempt to Take Control of Anavex VOTE “FOR” ONLY ANAVEX’S SIX NOMINEES ON THE WHITE UNIVERSAL PROXY CARD TODAY Your Vote is Important! If you have any questions or require WHITE Card any assistance with voting your shares, Vote FOR the following nominees only: please call: ❑ Peter Donh
Anavex Life Sciences — Proxy Contest (September 2026) on 6ix